Genetic determinants of prostate and breast cancer risk
View Patent ↗Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa) or aggressive PCa, or to developing breast cancer (BrCa).
1. A method comprising:
obtaining a blood sample comprising DNA from a subject who is suspected of being at risk of developing prostate cancer (PCa);
contacting the sample with oligonucleotide probes that are identical to at least 20 nucleotides of SEQ ID NO:6 and that terminate adjacent to the polymorphic site or encompass the polymorphic site at rs2063979 and detecting the genotype at rs2063979;
contacting the sample with oligonucleotide probes that are identical to at least 20 nucleotides of SEQ ID NO:8 and that terminate adjacent to the polymorphic site or encompass the polymorphic site at rs2228428 and detecting the genotype at rs2228428;
contacting the sample with oligonucleotide probes that are identical to at least 20 nucleotides of SEQ ID NO: 15 and that terminate adjacent to the polymorphic site or encompass the polymorphic site at rs4151117 and detecting the genotype at rs4151117;
contacting the sample with oligonucleotide probes that are identical to at least 20 nucleotides of SEQ ID NO:9 and that terminate adjacent to the polymorphic site or encompass the polymorphic site at rs223895 and detecting the genotype at rs223895;
contacting the sample with oligonucleotide probes that are identical to at least 20 nucleotides of SEQ ID NO:4 and that terminate adjacent to the polymorphic site or encompass the polymorphic site at rs16951657 and detecting the genotype at rs16951657; and
detecting levels of Prostate Serum Antigen (PSA) in a blood sample from the subject with a “GG” genotype at rs2063979, a “CT” genotype at rs2228428, a “GG” genotype at rs4151117, a “TT” genotype at rs223895, or at least one “T” allele at rs16951657.
2. The method of claim 1 , wherein the subject is a patient having one or more risk factors associated with PCa.
3. The method of claim 2 , wherein the risk factors associated with PCa include one or more of: age; race/ethnicity; nationality; family history; diet; obesity; lack of exercise; inflammation of the prostate; infection; and vasectomy.
4. The method of claim 1 , wherein the subject has one or more of a grandparent, parent, uncle, sibling, or child who has or had PCa.
5. The method of claim 1 further comprising performing an imaging study on the selected subject to detect the development of PCa or performing a prostate biopsy on the selected subject to detect cancerous cells.
6. The method of claim 1 further comprising administering a prophylactic treatment to the selected subject to decrease their risk of developing PCa.
7. The method of claim 1 further comprising administering a treatment for PCa to the selected subject.
8. The method of claim 7 , wherein the treatment is surgery; radiation therapy; or hormone therapy.
9. The method of claim 1 , wherein detecting the genotype comprises sequencing.
10. The method of claim 1 , wherein detecting the genotype comprises performing fluorescence polarization template-directed dye-terminator incorporation.
11. The method of claim 1 , wherein the probes are labeled.